期刊文献+

咪喹莫特对朗格汉斯细胞及角质形成细胞细胞因子mRNA表达及分泌水平的影响 被引量:3

Effects of Imiquimod on the mRNA expression and secretion of cytokines by human epidermal Langerhans cells and keratinocytes
原文传递
导出
摘要 目的观察咪喹莫特(Imiquimod)溶液对人表皮朗格汉斯细胞(LC)及永生化角质形成细胞(KC)株-HaCaT细胞细胞因子mRNA及分泌水平的影响,探讨其免疫调节机制。方法联用密度梯度离心及免疫磁珠法分离纯化人表皮LC,将LC及HaCaT细胞均各分为实验组和对照组,实验组加5μgml咪喹莫特,对照组不加药,处理4h后,提取总RNA,采用RTPCR法分别检测各组细胞中细胞因子TNFα、IL1β及IL6mRNA的表达量,取培养上清,用ELISA方法检测3种细胞因子的含量。结果LC实验组TNFα、IL1β及IL63种细胞因子mRNA表达量及分泌量均较对照组显著增高(P<0.05),而HaCaT细胞组加药后3种细胞因子mRNA表达量及分泌量较对照组未见明显增加(P>0.05)。结论5μgml咪喹莫特溶液能增加LC细胞因子TNFα、IL1β及IL6的mRNA表达量,但其对HaCaT细胞上述3种细胞因子mRNA表达量均未见有明显上调作用。 Objective To observe the effects of the Imiquimod solution on the mRNA expressions of cytokines(TNF-α, IL-1β and IL-6) and cytokine secretion from human epidermal Langerhans cells and human eternal cell lines--HaCaT kerafinocyte to illuminate the immunoregulation mechanisms of Imiquimod. Methods Langerhans cells were sorted by density gradient centrifugation and magnetic technique. Langerhans cells and HaCaT cells were divided into experimental group and control group. The solution of 5μg/ml Imiquimod was added to the experimental group. The total BNA and cell-free culture supematants were harvested 4 hours after application. BTPCR was conducted to detect the mRNA expressions of TNF-α, IL-1β and IL-6 in each group, cytokines secretion was determined by ELISA kits. Results Four Four after 5μg/ml Imiquimod application, expression levels of TNF-α, IL-1β and 1I.-6 mRNA and cytokines secretion from Langerhans cells were statistically higher than those of controls( P 〈 0.05). On the contrary, there was no statistically difference of the mRNA expression levels and cytokine secretion of TNF-α, IL-1β and IL-6 of HaCaT cells between the experimental group and the control group( P 〉0.05). Conclusion The solution of 5μg/ml Imiquimod can increase the mRNA expression and secretion of TNF-α, ID-1β and IL-6 in sorted Langerhans cells. But in the HaCaT cells, Imiquimod fags to increase the mRNA expression and secretion of the above cytokines.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2006年第3期274-278,共5页 Chinese Journal of Microbiology and Immunology
关键词 咪喹莫特 朗格汉斯细胞(LC) 角质形成细胞(KC) HaCaT细胞 细胞因子 RTPCR Imiquimod Langerhans cells Keratinocytes HaCaT cells Cytokine RT-PCR
  • 相关文献

参考文献11

  • 1Vilata JJ, Badia X. Effectiveness, satisfaction and compliance with Imiquimod in the treatment of external anogenital warts. International Journal of STD & AIDS, 2003, 14(1): 11-17.
  • 2Eklind J, Tartler U, MaschkeJ, et al. Imiquimod to treat different cancers of the epidermis.Dermatologic Surgery, 2003, 29(8): 890-896.
  • 3Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with Imiqiumod cream 5% : a report of six cases, Br J Dermatol, 2001, 144(5): 1051-1053.
  • 4缪旭,骆丹,吉玺,林向飞.联用密度梯度离心与免疫磁珠法分离纯化人表皮朗格汉斯细胞[J].临床皮肤科杂志,2005,34(5):276-278. 被引量:8
  • 5李英辉,刘军,薛采芳,丁劲,宫卫东,赵亚.靶向核糖核酸酶在体外抑制乙型肝炎病毒复制的研究[J].中华微生物学和免疫学杂志,2003,23(6):484-488. 被引量:3
  • 6Wager TL, Horton VL, Carlson GL, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, Imiquimod, S-16598 and S-17352. Cytokine, 1997, 9(11): 837-845.
  • 7Burns RP Jr, Ferbel B, Tomai M, et al. The Imidazoquinolines, Imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clinical Immunol, 2000, 1(94):13-23.
  • 8Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunodulator, Imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res, 1994, 13: 71-76.
  • 9Suzaki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol, 2000, 114 (1): 135-141.
  • 10Mempel M, Voelcke V, Kollisch G, et al. Toll-like receptor expression human keratinocytes: nuclear factor kB controlled gene activation by Staphylococcus aureus is Toll-like receptor 2 but not Toll-like receptor 4 or playlet activating factor receptor dependent. J Invest Dermatol, 2003,121(6) : 1389-1396.

二级参考文献26

  • 1郑茂荣,范青源,谢勇,牟贤龙,方跃明,顾美芳.Percoll密度梯度离心技术分离纯化豚鼠表皮Langerhans细胞 [J].中华皮肤科杂志,1995,28(5):296-298. 被引量:8
  • 2Natsoulis G, Boeke JD. New antiviral strategy using capsid-nuclease fusion proteins. Nature, 1991, 352(6336) : 632-635.
  • 3Natsoulis G, Seshaiah P, Federspiel MJ, et al. Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication. Proc Natl Acad Sci USA, 1995, 92(2): 364-368.
  • 4Melekhovets YF, Joshi S. Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specially recognizes and cleaves HIV-1 RNA in vitro. Nucleic Acids Res, 1996, 24 (10): 1908-1912.
  • 5Schumann G, Qin L, Rein A, et al. Therapeutic effect of Gag-nuclease fiasion protein on retrovirus-infected cell cultures. J Virol, 1996, 70(7):4329-4337.
  • 6VanBrocklin M, Ferris AL, Hughes SH, et al. Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyprptein significantly inhibits virus spread. J Virol, 1997, 71(4) : 3312-3318.
  • 7Wu X, Liu H, Xiao H. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. J Virol, 1995, 69:3389-3398.
  • 8Schumann G, Cannon K, Ma WP. Antiretroviral effect of a gag-RNase HI fusion gene.Gene Ther, 1997, 4: 593-599.
  • 9Schumann G, Hermankova M, Cannon K. Therapeutic effect of a gag-nu-clease fusion protein against retroviral infection in vivo. J Virol, 2001,75: 7030-7041.
  • 10Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell, 1982, 29:403-415.

共引文献9

同被引文献19

  • 1许金华,卢玉洁.瘢痕疙瘩的门诊治疗[J].河北医学,2005,11(6):565-567. 被引量:6
  • 2李志军,刘流,何黎.外用咪喹莫特的研究进展[J].国际皮肤性病学杂志,2006,32(3):144-146. 被引量:17
  • 3董达科,陈晓栋,王建力.咪喹莫特对瘢痕疙瘩成纤维细胞增殖和胶原产生的影响[J].中华皮肤科杂志,2006,39(10):568-570. 被引量:16
  • 4Meyer LJ,Russell SB,Russell JD,et al.Reduced hyaluronan in keloid tissue and cultured keloid fibroblasts.J Invest Dermatol,2000,114:953-959.
  • 5HeslingC,D IncanM,MansardS,et al.Invivo and insitumodu-lation of the expression of genesinvolved in metastasis and angio-genesis in apatient treated with topical imiquimod for melanomask in metastases.Br J Dermatol,2004,150:761-767.
  • 6Berman B,Villa A.Imiquimod 5%cream for keloid management.Dermatol Surg,2003,29:1050-1051.
  • 7Prado A,Andrades P,Benitez S,et al.Scar management after breast surgery:preliminary results of a prospective,randomized,and double-blind clinical study with aldara cream 5%(imiquimod).Plast Reconstr Surg,2005,115:966-972.
  • 8Al-Attar A,Mess S,Thomassen JM,et al.Keloid pathogenesis and treatment[J].Plast Reconstr Surg,2006,117(1):286-300.
  • 9Coors EA,Schuler G,Von Den Driesch P.Topical imiquimod as treatment for different kinds of cutaneous lymphoma[J].Eur J Dermatol,2006,16(4):391-393.
  • 10Imbertson LM,Beaurline JM,Couture AM,et al.Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463[J].J Invest Dermatol,1998,110(5):734-739.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部